Blood-brain barrier P-glycoprotein function in healthy subjects and Alzheimer's disease patients: Effect of polymorphisms in the ABCB1 gene

EJNMMI Research

Volumn 2, Issue 1, 2012, Pages 1-6

  van Assema, Daniëlle M E ^a   Lubberink, Mark ^b   Rizzu, Patrizia ^c   van Swieten, John C ^d   Schuit, Robert C ^c   Eriksson, Jonas ^b   Scheltens, Philip ^a   Koepp, Matthias ^e   Lammertsma, Adriaan A ^c   van Berckel, Bart N M ^c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

ABCB1; Blood brain barrier; MDR1; P glycoprotein; PET; Polymorphisms

Indexed keywords

ADENINE; AMYLOID BETA PROTEIN; BRAIN PROTEIN; CYTOSINE; DNA; GUANINE; MULTIDRUG RESISTANCE PROTEIN; RADIOPHARMACEUTICAL AGENT; THYMINE; UNCLASSIFIED DRUG; VERAPAMIL C 11;

ABCB1 GENE; ADULT; ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DNA ISOLATION; DNA POLYMORPHISM; FEMALE; GENE; GENE AMPLIFICATION; GENETIC VARIABILITY; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYMERASE CHAIN REACTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84875319920     PISSN: None     EISSN: 2191219X     Source Type: Journal    
DOI: 10.1186/2191-219X-2-57     Document Type: Article

References (30)

1. Fromm MF: Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 2004, 25:423-429.
2. Schinkel AH: P-glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev 1999, 36:179-194.
3. Vogelgesang S, Jedlitschky G, Brenn A, Walker LC: The role of the ATP-binding cassette transporter P-glycoprotein in the transport of beta-amyloid across the blood-brain barrier. Curr Pharm Des 2011, 17:2778-2786.
4. van Assema DM, Lubberink M, Bauer M, van der Flier WM, Schuit RC, Windhorst AD, Comans EF, Hoetjes NJ, Tolboom N, Langer O, Müller M, Scheltens P, Lammertsma AA, van Berckel BN: Blood-brain barrier Pglycoprotein function in Alzheimer's disease. Brain 2012, 135:181-189.
5. Kerb R: Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett 2006, 234:4-33.
6. Cascorbi I: P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations. Handb Exp Pharmacol 2011, 201:261-283.
7. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, Schaeffeler E, Eichelbaum M, Brinkmann U, Roots I: Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001, 69:169-174.
8. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000, 97:3473-3478.
9. Sakaeda T, Nakamura T, Horinouchi M, Kakumoto M, Ohmoto N, Sakai T, Morita Y, Tamura T, Aoyama N, Hirai M, Kasuga M, Okumura K: MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res 2001, 18:1400-1404.
10. Nakamura T, Sakaeda T, Horinouchi M, Tamura T, Aoyama N, Shirakawa T, Matsuo M, Kasuga M, Okumura K: Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther 2002, 71:297-303.
11. Kimchi-Sarfaty C, Gribar JJ, Gottesman MM: Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. MolPharmacol 2002, 62:1-6.
12. Morita N, Yasumori T, Nakayama K: Human MDR1 polymorphism: G2677T/ A and C3435T have no effect on MDR1 transport activities. Biochem Pharmacol 2003, 65:1843-1852.
13. Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, Takahashi M, Kurata Y, Kigawa J, Higuchi S, Terakawa N, Otsubo K: Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 2001, 297:1137-1143.
14. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, Lan LB, Schuetz JD, Schuetz EG, Wilkinson GR: Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001, 70:189-199.
15. Horinouchi M, Sakaeda T, Nakamura T, Morita Y, Tamura T, Aoyama N, Kasuga M, Okumura K: Significant genetic linkage of MDR1 polymorphisms at positions 3435 and 2677: functional relevance to pharmacokinetics of digoxin. Pharm Res 2002, 19:1581-1585.
16. Brunner M, Langer O, Sunder-Plassmann R, Dobrozemsky G, Muller U, Wadsak W, Krcal A, Karch R, Mannhalter C, Dudczak R, Kletter K, Steiner I, Baumgartner C, Müller M: Influence of functional haplotypes in the drug transporter gene ABCB1 on central nervous system drug distribution in humans. Clin Pharmacol Ther 2005, 78:182-190.
17. 11C-verapamil. J Nucl Med 2006, 47:1427-1433.
18. Bart J, Groen HJ, Hendrikse NH, van der Graaf WT, Vaalburg W, de Vries EG: The blood-brain barrier and oncology: new insights into function and modulation. Cancer Treat Rev 2000, 26:449-462.
19. Didziapetris R, Japertas P, Avdeef A, Petrauskas A: Classification analysis of P-glycoprotein substrate specificity. J Drug Target 2003, 11:391-406.
20. Folstein MF, Folstein SE, McHugh PR: "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975, 12:189-198.
21. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
22. 18F]FDDNP PET images. J Neurol Neurosurg Psychiatry 2010, 81:882-884.
23. Brix G, Zaers J, Adam LE, Bellemann ME, Ostertag H, Trojan H, Haberkorn U, Doll J, Oberdorfer F, Lorenz WJ: Performance evaluation of a whole-body PET scanner using the NEMA protocol. National Electrical Manufacturers Association. J Nucl Med 1997, 38:1614-1623.
24. Boellaard R, van Lingen A, van Balen SC, Hoving BG, Lammertsma AA: Characteristics of a new fully programmable blood sampling device for monitoring blood radioactivity during PET. Eur J Nucl Med 2001, 28:81-89.
25. Svarer C, Madsen K, Hasselbalch SG, Pinborg LH, Haugbol S, Frokjaer VG, Holm S, Paulson OB, Knudsen GM: MR-based automatic delineation of volumes of interest in human brain PET images using probability maps. Neuroimage 2005, 24:969-979.
26. 11C]WAY-100635 for PET. Neuroimage 1998, 8:426-440.
27. 11C] verapamil and PET. J Cereb Blood Flow Metab 2007, 27:424-433.
28. 11C]verapamil studies. EJNMMI Res 2012, 2:1.
29. Dutheil F, Beaune P, Tzourio C, Loriot MA, Elbaz A: Interaction between ABCB1 and professional exposure to organochlorine insecticides in Parkinson disease. Arch Neurol 2010, 67(6):739-745.
30. Frankfort SV, Doodeman VD, Bakker R, Tulner LR, van Campen JP, Smits PH, Beijnen JH: ABCB1 genotypes and haplotypes in patients with dementia and age-matched non-demented control patients. Mol Neurodegener 2006, 1:13.